Matinas BioPharma
MTNB
67 hedge funds and large institutions have $33.5M invested in Matinas BioPharma in 2021 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 13 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
15% more capital invested
Capital invested by funds: $29.2M → $33.5M (+$4.24M)
0% more funds holding
Funds holding: 67 → 67 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
0.13% less ownership
Funds ownership: 0.37% → 0.24% (-0.13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
+$907K |
| 2 |
AWA
Arkadios Wealth Advisors
Atlanta,
Georgia
|
+$905K |
| 3 |
VF
Virtu Financial
New York
|
+$199K |
| 4 |
CCM
Courage Capital Management
Nashville,
Tennessee
|
+$173K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$160K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$8.89M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$812K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$768K |
| 4 |
Renaissance Technologies
New York
|
-$472K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$465K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Squarepoint
New York
| – | -$12K | -322 | Closed |
|
|
FDCDDQ
77
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$11.9K | -306 | Closed |
|
|
OAM
78
Occidental Asset Management
Burlingame,
California
| – | -$9K | -240 | Closed |
|
79
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$9K | -239 | Closed |
|
80
Franklin Resources
San Mateo,
California
| – | -$8K | -200 | Closed |
|
MTNB Hedge Fund Activity: Q3 2021 in Review
67 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2021, worth a combined $33.5M — up 15% from $29.2M a quarter earlier.
Fund positioning in MTNB was balanced in Q3 2021: 13 funds opened new positions, 13 closed out, 21 added to existing stakes and 9 trimmed.
The largest buyer was Sargent Investment Group, adding an estimated $907K. The largest seller was Boxer Capital, exiting entirely with an estimated $8.89M sold.
- 67 institutional investors held Matinas BioPharma (MTNB) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $33.5M of Matinas BioPharma stock for Q3 2021, up 15% quarter-over-quarter.
- 13 funds opened new Matinas BioPharma positions in Q3 2021 and 13 closed out, a net change of 0 holders.
- The largest Matinas BioPharma buyer in Q3 2021 was Sargent Investment Group, an estimated $907K added.
- The largest Matinas BioPharma seller in Q3 2021 was Boxer Capital, an estimated $8.89M sold.
Based on aggregated 13F filings for Q3 2021.